DaVita Inc. 10-Q Summary: Quarter Ended September 30, 2002
Business Context and Reporting Period
This Form 10-Q covers the three and nine months ended September 30, 2002, for DaVita Inc., a provider of dialysis services. The reporting period is characterized by a major recapitalization event involving debt restructuring and significant common stock repurchases. The company operates primarily in the continental United States, having completed the divestiture of non-continental operations in the second quarter of 2002.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2002 | Nine Months Ended Sep 30, 2002 |
|---|---|---|
| Net Operating Revenues | $481.2 million | $1,351.5 million |
| Operating Income | $111.3 million | $271.2 million |
| Net Income | $54.2 million | $98.5 million |
| Diluted EPS (Net Income) | $0.72 | $1.20 |
| Cash and Cash Equivalents | $115.4 million (Sep 30, 2002) | N/A |
| Long-Term Debt | $1,313.8 million (Sep 30, 2002) | N/A |
| Operating Cash Flow (9 months) | N/A | $282.2 million |
Margin Analysis: Operating margins for continental U.S. operations were approximately 19% for the quarter, compared to 20% in the prior year quarter, excluding prior-period service recoveries. Center operating expenses were approximately 68% of net operating revenues.
Material Changes vs. Prior Period
- Recapitalization and Debt Restructuring: In April 2002, the company retired $225 million of Senior Subordinated Notes for $266 million, incurring an extraordinary loss of $29.4 million (net of tax). Concurrently, a new $1.115 billion senior credit facility was secured.
- Stock Repurchases: The company repurchased approximately 25.4 million shares for $597.2 million during the nine-month period, including a tender offer in June 2002. This significantly reduced shareholders' equity from $503.6 million (Dec 31, 2001) to $48.7 million (Sep 30, 2002).
- Revenue Growth: Net operating revenues increased 10.8% year-over-year for the quarter. Continental U.S. dialysis revenue grew 10%, driven by a 1.5% increase in average revenue per treatment and a 3.8% to 4.6% same-center growth rate.
- Florida Laboratory Recovery: Following a favorable administrative law judge ruling, the company began recognizing revenue from prior-period Medicare lab claims. $27.2 million in cash collections were recognized in the third quarter, and current-period lab revenue of $5.4 million was recognized.
- Accounting Standards: Adoption of SFAS No. 142 eliminated goodwill amortization, reducing expenses compared to prior periods where amortization was recorded.
Guidance, Outlook, and Risks
Outlook: Management projects quarterly EBITDA (excluding prior-period recoveries) to remain in the range of $95 million to $100 million through 2003, with full-year 2003 recurring EBITDA projected between $380 million and $400 million. Same-center growth is expected to range from 3.0% to 5.0% through 2003.
Risks and Contingencies:
- Regulatory Investigations: The company is subject to ongoing reviews by the U.S. Attorney's Office and the Office of Inspector General (OIG) regarding billing practices and physician relationships. A third-party carrier review of the Florida laboratory remains active, though recent rulings have been favorable.
- Reimbursement Rates: Approximately 51% of revenue comes from Medicare. There is a risk of future declines or lack of increases in reimbursement rates, particularly if ancillary services (like EPO administration) are bundled into the composite rate without sufficient compensation.
- Pharmaceutical Costs: EPO administration accounts for ~40% of revenue. Risks include price increases by the sole supplier (Amgen) and changes in clinical practice patterns.
- Liquidity: While the company believes it has sufficient liquidity, it carries significant debt obligations ($1.3 billion long-term) and must comply with financial covenants in its new credit facility.
Investor Verification Checklist
- Debt Covenants: Verify continued compliance with the financial covenants of the new $1.115 billion senior credit facility.
- Florida Lab Resolution: Monitor the status of the remaining review periods for the Florida laboratory and the finality of the administrative law judge's ruling.
- Government Investigations: Track developments in the OIG and U.S. Attorney's Office inquiries regarding billing and physician relationships.
- Medicare Policy Changes: Assess the impact of potential changes to the Medicare ESRD composite rate, specifically regarding the inclusion of pharmaceuticals and laboratory services.
- Stock Repurchase Authorization: Confirm the remaining balance of the $225 million stock repurchase authorization and the pace of future buybacks.